News

Cystic Fibrosis Foundation9h
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy
BETHESDA, Md. (July 16, 2025) – Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million ...
Prime Medicine Shares Drop After New Funding, Equity Investment
Prime Medicine shares were 9.2% lower, at $3.90, after the company said the Cystic Fibrosis Foundation has agreed to provide it with up to $24 million in additional funding--including a $6 million ...
The Bakersfield Californian10h
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis ...
Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- ...
Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data
Prime Medicine Inc. (NASDAQ:PRME) is one of the best hot stocks to buy according to Wall Street analysts. In May, Prime ...
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications
Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...
STAT7h
FDA questions safety of GSK’s multiple myeloma drug
From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...